PriceTargets.com logo

ResMed - RMD Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $225.70
  • Forecasted Upside: -6.56%
  • Number of Analysts: 12
  • Breakdown:
  • 1 Sell Ratings
  • 5 Hold Ratings
  • 5 Buy Ratings
  • 1 Strong Buy Ratings
$241.55 As of 11/20/2024 01:00 AM ET
▲ +3.43 (1.44%)

This chart shows the closing price for RMD by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New ResMed Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for RMD and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for RMD

Analyst Price Target is $225.70
▼ -6.56% Downside Potential
This price target is based on 12 analysts offering 12 month price targets for ResMed in the last 3 months. The average price target is $225.70, with a high forecast of $283.00 and a low forecast of $180.00. The average price target represents a -6.56% upside from the last price of $241.55.

This chart shows the closing price for RMD for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 12 polled investment analysts is to moderate buy stock in ResMed. This rating has held steady since September 2024, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
5/30/2023
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
8/28/2023
  • 0 strong buy ratings
  • 9 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
11/26/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
2/24/2024
  • 0 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
5/24/2024
  • 0 strong buy ratings
  • 6 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
8/22/2024
  • 1 strong buy ratings
  • 6 buy ratings
  • 5 hold ratings
  • 1 sell ratings
Ratings as of
10/21/2024
  • 1 strong buy ratings
  • 5 buy ratings
  • 5 hold ratings
  • 1 sell ratings
Ratings as of
11/20/2024

Latest Recommendations

  • 1 strong buy ratings
  • 5 buy ratings
  • 5 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/25/2024KeyCorpBoost TargetOverweight ➝ Overweight$251.00 ➝ $266.00
10/25/2024Royal Bank of CanadaBoost TargetSector Perform ➝ Sector Perform$224.00 ➝ $232.00
10/25/2024Needham & Company LLCReiterated RatingHold
10/25/2024Robert W. BairdBoost TargetOutperform ➝ Outperform$280.00 ➝ $283.00
10/1/2024Royal Bank of CanadaBoost TargetSector Perform ➝ Sector Perform$206.00 ➝ $224.00
10/1/2024Needham & Company LLCReiterated RatingHold
9/26/2024Bank of AmericaBoost TargetBuy ➝ Buy$240.00 ➝ $270.00
9/24/2024Baird R WUpgradeStrong-Buy
9/24/2024Robert W. BairdInitiated CoverageOutperform$280.00
9/18/2024Wolfe ResearchReiterated RatingPeer Perform ➝ Underperform$180.00
9/18/2024Needham & Company LLCReiterated RatingHold
9/4/2024Needham & Company LLCDowngradeBuy ➝ Hold$236.00
8/2/2024Royal Bank of CanadaBoost TargetSector Perform ➝ Sector Perform$204.00 ➝ $206.00
8/2/2024KeyCorpBoost TargetOverweight ➝ Overweight$238.00 ➝ $251.00
8/2/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$236.00 ➝ $236.00
7/23/2024Royal Bank of CanadaBoost TargetSector Perform ➝ Sector Perform$200.00 ➝ $204.00
6/25/2024OppenheimerDowngradeOutperform ➝ Market Perform
6/24/2024CitigroupDowngradeBuy ➝ Neutral
6/24/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$236.00 ➝ $236.00
4/26/2024OppenheimerLower TargetOutperform ➝ Outperform$205.00 ➝ $200.00
4/26/2024Royal Bank of CanadaBoost TargetSector Perform ➝ Sector Perform$187.00 ➝ $200.00
4/26/2024KeyCorpBoost TargetOverweight ➝ Overweight$227.00 ➝ $238.00
4/26/2024Needham & Company LLCBoost TargetBuy ➝ Buy$224.00 ➝ $236.00
4/1/2024Needham & Company LLCBoost TargetBuy ➝ Buy$215.00 ➝ $224.00
3/27/2024MizuhoReiterated RatingBuy ➝ Buy$215.00
2/6/2024KeyCorpInitiated CoverageOverweight$227.00
1/30/2024OppenheimerBoost TargetOutperform ➝ Outperform$185.00 ➝ $205.00
1/26/2024MizuhoBoost TargetBuy ➝ Buy$180.00 ➝ $195.00
1/25/2024UBS GroupBoost TargetNeutral ➝ Neutral$175.00 ➝ $180.00
1/25/2024Royal Bank of CanadaBoost TargetSector Perform ➝ Sector Perform$181.00 ➝ $182.00
1/25/2024Needham & Company LLCBoost TargetBuy ➝ Buy$180.00 ➝ $215.00
1/9/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$160.00 ➝ $195.00
10/31/2023MizuhoLower TargetBuy ➝ Buy$180.00 ➝ $160.00
10/27/2023Morgan StanleyUpgradeEqual Weight ➝ Overweight$180.00 ➝ $169.00
10/16/2023OppenheimerLower TargetOutperform ➝ Outperform$275.00 ➝ $175.00
10/12/2023Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$273.00 ➝ $202.00
10/9/2023JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$210.00 ➝ $170.00
10/5/2023Jefferies Financial GroupLower Target$240.00 ➝ $165.00
9/29/2023Wolfe ResearchDowngradeOutperform ➝ Peer Perform
9/18/2023Bank of AmericaLower TargetBuy ➝ Buy$250.00 ➝ $230.00
9/13/2023MizuhoLower TargetBuy ➝ Buy$255.00 ➝ $180.00
9/6/2023Needham & Company LLCUpgradeHold ➝ Buy
9/5/2023UBS GroupDowngradeBuy ➝ Neutral
8/14/2023Royal Bank of CanadaLower TargetOutperform ➝ Outperform$284.00 ➝ $273.00
8/4/2023Bank of AmericaLower TargetBuy ➝ Buy$260.00 ➝ $250.00
8/4/2023KeyCorpLower TargetOverweight ➝ Overweight$280.00 ➝ $260.00
8/1/2023Royal Bank of CanadaUpgradeSector Perform ➝ Outperform$262.00 ➝ $284.00
5/22/2023UBS GroupInitiated CoverageBuy$290.00
4/13/2023MizuhoInitiated CoverageBuy$255.00
1/31/2023William BlairReiterated RatingOutperform
1/27/2023JPMorgan Chase & Co.Boost TargetOverweight$245.00 ➝ $260.00
1/18/2023CitigroupUpgradeNeutral ➝ Buy
1/17/2023JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$245.00
10/28/2022Royal Bank of CanadaBoost TargetSector Perform$252.00 ➝ $254.00
10/28/2022CitigroupDowngradeBuy ➝ Neutral
10/28/2022KeyCorpBoost TargetOverweight$276.00 ➝ $280.00
10/20/2022Bank of AmericaUpgradeNeutral ➝ Buy$245.00 ➝ $260.00
10/12/2022Jefferies Financial GroupInitiated CoverageHold$245.00
9/8/2022CitigroupUpgradeNeutral ➝ Buy
8/12/2022JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral
8/12/2022Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$246.00 ➝ $252.00
8/12/2022CitigroupDowngradeBuy ➝ Neutral
6/6/2022Royal Bank of CanadaUpgradeSector Perform ➝ Outperform$233.00 ➝ $244.00
4/5/2022Wolfe ResearchInitiated CoverageOutperform$280.00
1/31/2022CitigroupUpgradeNeutral ➝ Buy
1/30/2022The Goldman Sachs GroupUpgradeNeutral ➝ Buy
1/28/2022Robert W. BairdLower Target$300.00 ➝ $280.00
1/28/2022Royal Bank of CanadaUpgradeUnderperform ➝ Sector Perform$234.00 ➝ $241.00
1/24/2022JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$260.00 ➝ $270.00
1/24/2022Bank of AmericaUpgradeUnderperform ➝ Neutral$239.00 ➝ $250.00
1/13/2022Robert W. BairdUpgradeNeutral ➝ Outperform$270.00 ➝ $300.00
1/13/2022Royal Bank of CanadaBoost TargetUnderperform$227.00 ➝ $234.00
12/6/2021MacquarieUpgradeNeutral ➝ Outperform
10/29/2021Royal Bank of CanadaLower TargetUnderperform$233.00 ➝ $227.00
10/22/2021CLSAUpgradeUnderperform ➝ Outperform
8/9/2021CLSAUpgradeSell ➝ Underperform
8/9/2021Needham & Company LLCReiterated RatingHold
8/2/2021CLSADowngradeOutperform ➝ Sell
8/2/2021Needham & Company LLCDowngradeBuy ➝ Hold
7/28/2021Jefferies Financial GroupUpgradeUnderperform ➝ Hold$170.00 ➝ $240.00
7/27/2021Royal Bank of CanadaBoost TargetUnderperform$223.00 ➝ $238.00
7/26/2021JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$245.00 ➝ $246.00
7/13/2021Royal Bank of CanadaInitiated CoverageUnderperform$223.00
6/28/2021CitigroupDowngradeBuy ➝ Neutral
6/22/2021MacquarieUpgradeNeutral ➝ Outperform
6/21/2021Robert W. BairdInitiated CoverageNeutral$240.00
6/21/2021Needham & Company LLCBoost TargetPositive ➝ Buy$229.00 ➝ $267.00
6/16/2021Bank of AmericaDowngradeNeutral ➝ Underperform$216.00 ➝ $221.00
6/15/2021OppenheimerBoost TargetOutperform$240.00 ➝ $270.00
6/14/2021Needham & Company LLCInitiated CoverageBuy$229.00
6/9/2021CLSAUpgradeSell ➝ Outperform
5/21/2021JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$206.00 ➝ $219.00
5/11/2021CitigroupUpgradeNeutral ➝ Buy
4/30/2021CitigroupDowngradeBuy ➝ Neutral
3/16/2021Needham & Company LLCUpgradeHold ➝ Buy$229.00
1/29/2021Needham & Company LLCReiterated RatingHold
11/2/2020UBS GroupUpgradeNeutral ➝ Buy$210.00
10/30/2020Credit Suisse GroupUpgradeNeutral ➝ Outperform
10/30/2020JPMorgan Chase & Co.UpgradeUnderweight ➝ Neutral$165.00
10/27/2020Bank of AmericaUpgradeUnderperform ➝ Neutral$186.00
8/6/2020Morgan StanleyDowngradeOverweight ➝ Equal Weight
8/6/2020OppenheimerBoost Target$200.00 ➝ $210.00
8/6/2020The Goldman Sachs GroupDowngradeBuy ➝ Neutral
8/6/2020Needham & Company LLCReiterated RatingHold
8/5/2020OppenheimerInitiated CoverageBuy$212.00
8/3/2020Bank of AmericaDowngradeBuy ➝ Underperform
6/17/2020Morgan StanleyUpgradeEqual Weight ➝ Overweight$176.00
5/1/2020JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight
4/30/2020Needham & Company LLCInitiated CoverageHold
4/30/2020OppenheimerUpgradeMarket Perform ➝ Outperform$200.00
3/26/2020Credit Suisse GroupDowngradeOutperform ➝ Neutral
3/24/2020William BlairReiterated RatingBuy
2/18/2020Morgan StanleyDowngradeOverweight ➝ Equal Weight$165.00
2/3/2020CLSAInitiated CoverageUnderperform
1/31/2020UBS GroupDowngradeBuy ➝ Neutral$174.00
1/9/2020OppenheimerInitiated CoverageHold
11/22/2019KeyCorpInitiated CoverageSector Weight ➝ Sector Weight
(Data available from 11/21/2019 forward)

News Sentiment Rating

1.16 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 20 very positive mentions
  • 12 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
4/24/2024
  • 35 very positive mentions
  • 22 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/24/2024
  • 21 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/23/2024
  • 19 very positive mentions
  • 5 positive mentions
  • 4 negative mentions
  • 1 very negative mentions
Mentions as of
7/23/2024
  • 26 very positive mentions
  • 22 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/22/2024
  • 36 very positive mentions
  • 19 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
9/21/2024
  • 31 very positive mentions
  • 18 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/21/2024
  • 42 very positive mentions
  • 18 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
11/20/2024

Current Sentiment

  • 42 very positive mentions
  • 18 positive mentions
  • 0 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

ResMed logo
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME) to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies; and MEDIFOX DAN's software solutions. The company markets its products to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $241.55
Low: $236.72
High: $242.47

50 Day Range

MA: $242.10
Low: $231.43
High: $256.07

52 Week Range

Now: $241.55
Low: $150.39
High: $260.49

Volume

549,312 shs

Average Volume

1,043,885 shs

Market Capitalization

$35.46 billion

P/E Ratio

31.99

Dividend Yield

0.89%

Beta

0.69

Frequently Asked Questions

What sell-side analysts currently cover shares of ResMed?

The following Wall Street sell-side analysts have issued stock ratings on ResMed in the last year: Baird R W, Bank of America Co., Citigroup Inc., JPMorgan Chase & Co., KeyCorp, Mizuho, Needham & Company LLC, Oppenheimer Holdings Inc., Robert W. Baird, Royal Bank of Canada, StockNews.com, UBS Group AG, and Wolfe Research.
View the latest analyst ratings for RMD.

What is the current price target for ResMed?

0 Wall Street analysts have set twelve-month price targets for ResMed in the last year. Their average twelve-month price target is $225.70, suggesting a possible downside of 6.6%. Robert W. Baird has the highest price target set, predicting RMD will reach $283.00 in the next twelve months. UBS Group AG has the lowest price target set, forecasting a price of $180.00 for ResMed in the next year.
View the latest price targets for RMD.

What is the current consensus analyst rating for ResMed?

ResMed currently has 1 sell rating, 5 hold ratings, 5 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for RMD.

What other companies compete with ResMed?

Other companies that are similar to ResMed include Boston Scientific, Medtronic, Becton, Dickinson and Company, Edwards Lifesciences and IDEXX Laboratories. Learn More about companies similar to ResMed.

How do I contact ResMed's investor relations team?

ResMed's physical mailing address is 9001 SPECTRUM CENTER BLVD., SAN DIEGO CA, 92123. The medical equipment provider's listed phone number is (858) 836-5000 and its investor relations email address is [email protected]. The official website for ResMed is www.resmed.com. Learn More about contacing ResMed investor relations.